Home / Biosimilars / General / Call for action on labelling of biosimilars

Call for action on labelling of biosimilars Posted 26/09/2014

European trade association, the European Association for Bioindustry (EuropaBio) has called on the European Medicines Agency (EMA) to define specific guidance on the labelling of biosimilars.

EuropaBio published a statement on 15 September 2014 giving the perspective of the healthcare biotechnology industry on the labelling of biosimilars. In the statement, Members of the EuropaBio Healthcare Council called for specific guidance on the labelling of biosimilars, in order to take into account the specificities of these products and facilitate their understanding and acceptance by patients and physicians.

The association is calling for ‘biosimilars need to be labelled in a clear and transparent way’, which they believe will allow physicians ‘to make informed decisions when selecting the most appropriate medicinal product for their patients’.

EuropaBio points out that currently the format and content of labelling is governed by EMA’s Quality Review of Documents guidance (EMA/627621/2011), which does not distinguish between biosimilars, generics and hybrid products.

In its proposal, EuropaBio suggests the labelling of biosimilars should combine information on both the biosimilar and the reference product, so that it is clear whether the data presented was generated for the reference or the biosimilar product, and which indications have been approved for each product.

The Association of the British Pharmaceutical Industry (ABPI), which represents innovative research-based biopharmaceutical companies in the UK, has also given a similar recommendation in its position paper on biosimilars [1]. The ABPI recommends that the summary of product characteristics (SmPC) for a biosimilar should clearly indicate the source of information contained within it, such as relevant data from its clinical development programme and clinical data derived from the reference biological.

Related articles
European trade organizations worried about pharmacovigilance fees

EU publishes consensus report on biosimilars

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. ABPI issues updated position paper on biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Sep 26]. Available from: www.gabionline.net/Biosimilars/General/ABPI-issues-updated-position-paper-on-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.

Source: EuropaBio

Comments (0)